TOPLINE: In patients with type 2 diabetes (T2D), combination therapy with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and thiazolidinediones was associated with a reduced risk for all-cause mortality, cardiovascular mortality, and major adverse cardiovascular events (MACEs) compared with those who used none or one of these therapies. METHODOLOGY: For people with T2D, the potential … Read more
TOPLINE: Regular use of glucosamine, a widely used supplement to manage osteoarthritis and joint pain, was linked to reduced risks for both composite microvascular complications and diabetic nephropathy among patients with type 2 diabetes (T2D). METHODOLOGY: Glucosamine, used daily by about 20% of US and Australian adults to treat osteoarthritis and joint pain, has been … Read more
Over a span of several months, I helped care for three separate patients taking sodium-glucose cotransporter-2 (SGLT2) inhibitors for at least the past 2 years who presented to the ICU with euglycemic diabetic ketoacidosis (DKA) within a few weeks of initiating a keto diet. These days, SGLT2 inhibitors are being prescribed so frequently, it sometimes … Read more
The increasing use of technology for treating type 1 diabetes (T1D) has improved glycemic control; however, it hasn’t eliminated the risk for diabetic ketoacidosis (DKA). In fact, without early recognition, insulin pump malfunctions can directly lead to DKA. Currently, patients test ketones at home using urine test strips that measure acetoacetate (the primary ketone body) … Read more
TOPLINE: Low levels of soluble neuropilin-1 (sNRP-1) were associated with depression in patients with newly diagnosed type 2 diabetes (T2D), with the association remaining consistent across all age groups. METHODOLOGY: The NRP-1 receptor is an essential transmembrane glycoprotein involved in the development of the nervous and cardiovascular systems, as well as immune regulation, and may … Read more
The popularity of glucagon-like peptide 1 (GLP-1) receptor agonists has led to a concomitant increase in the need to understand the potential perioperative ramifications of taking these drugs, from increased aspiration risk to prosthetic joint infections. At the American Academy of Orthopaedic Surgeons 2025 Annual Meeting, researchers presented an array of studies looking at the … Read more
Is obesity among the most misunderstood, misclassified, and mistreated diseases? Over the past 30 years, researchers have not only identified a key hormone (leptin) that helps regulate appetite and body weight, but they’ve also determined the biologic underpinnings (eg, altered central nervous system pathways associated with energy balance) and discovered that obesity is often genetically … Read more
TOPLINE: Individuals with type 1 diabetes had more than twice the risk for ischaemic stroke and an 88% higher risk for haemorrhagic stroke than control individuals, whereas those with type 2 diabetes had a 37% higher risk for ischaemic stroke, with no significant impact on the risk for haemorrhagic stroke. METHODOLOGY: This Sweden-wide cohort study … Read more
Archyde Do Weight Loss Drugs Like Ozempic Increase Suicide Risk? New Study Offers Reassuring Data Table of Contents 1. Do Weight Loss Drugs Like Ozempic Increase Suicide Risk? New Study Offers Reassuring Data 2. Key Findings: GLP-1 RAs and Suicidality 3. Delving into the Methodology 4. Beyond the Numbers: A Nuanced Perspective 5. Putting the … Read more
TOPLINE: A meta-analysis of randomized controlled trials involving over 59,000 patients with diabetes or obesity showed no statistically significant difference in the risk for suicide between those treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and placebo. METHODOLOGY: Initial reports of increased suicidality in GLP-1 RA users compared with the general population raised concerns … Read more